Actively Recruiting
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2024-06-06
30
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial included 30 cases and aimed to understand the effectiveness and safety of the VMAC regimen combined with donor lymphocyte infusion (DLI) in the treatment of patients with acute myeloid leukemia who have relapsed after allogeneic hematopoietic stem cell transplantation. The main questions it aims to answer are: The safety and efficacy of VMAC combined with DLI in the treatment of allo HSCT recurrence in AML patients;
CONDITIONS
Official Title
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute myeloid leukemia confirmed by bone marrow morphology with at least 5% blast cells after allogeneic hematopoietic stem cell transplantation
- Age between 18 and 65 years, any gender
- Eastern Oncology Cooperative Group (ECOG) performance status score of 0 to 2
- Signed informed consent form by the patient or legal guardian before starting the study
You will not qualify if you...
- Patients who have had a secondary transplant
- History of other tumors treated within the past 3 years, except for certain skin cancers and carcinoma in situ
- Positive for HIV, active hepatitis B or C, or syphilis infections
- Mental illness or other conditions preventing cooperation with study procedures
- Pregnant or unable to use effective contraception during treatment
- Active heart disease including long QTc syndrome, severe arrhythmias, heart failure class II or higher, low left ventricular ejection fraction, recent myocardial infarction, or other severe heart conditions
- Transplantation from an unrelated donor
- Deemed unsuitable for the study by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, China, 300000
Actively Recruiting
Research Team
X
Xin Chen, Doctor
CONTACT
X
Xueou Liu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here